"Delivering medicine where it matters."
PATENT PENDING
A new disruptive inhalation technology enabling precision delivery of medication to the lungs, reducing side effects, and lowering environmental impact.
ExactHaler® is a passive add-on device for existing inhalers, developed to optimize the delivery of inhaled medication to the small airways of the lungs.
Advancing inhalation therapy for over 700 million Asthma and COPD patients worldwide.
Since the introduction of modern inhalers, a significant proportion of the delivered medication has been deposited in the mouth and throat rather than reaching the lungs.
This may result in:
Variable treatment efficacy
Unnecessary drug waste
Local side effects
Increased environmental impact
ExactHaler® has been developed as a simple, passive add-on device without electronics or moving parts.
The technology:
Can be used with existing inhalers
Controls and encapsulates aerosol transport through the oral cavity
Reduces unwanted deposition of medicine the mouth and throat
Has great potential for increasing lung deposition
Can reduce the required medication dose
ExactHaler® is the result of several years of development focused on:
Aerosol transport
Flow dynamics
Reproducible inhalation
Patient-friendly use
The device contains no electronics, batteries, or mechanical components.
ExactHaler® is being developed with the ambition to achieve:
Reduced drug waste
Potential dose reduction
Lower propellant consumption
Reduced carbon footprint from inhalation therapy
This supports both improved patient care and future sustainability goals within respiratory medicine.
Contact us at crj@reipurthmedical.com for more info on the project
Reipurth Medical ApS
Lyngby Hovedgade 49A
DK-2800 Kgs Lyngby
+45 30502558